header image

Últimas notícias

Approval of Dedicated Step for Specific Prion Removal and Second Manufacturing Site for octaplas® Through a Mutual Recognition Procedure in Europe


Octapharma AG, Lachen, Switzerland In order to further enhance the safety of octaplas® against the theoretical risk of transmitting the prion disease called variant Creutzfeldt-Jakob disease (vCJD), a chromatographic step to...

Octapharma Chairman receives prestigious award in Vienna


Wolfgang Marguerre has been honored with the Grand Decoration of Honor in Gold (Grosses Goldenes Ehrenzeichen) for Services to the Republic of Austria. Mr Wolfgang Marguerre was selected for this illustrious award by Federal...

FDA Approves U.S. Market Return for octagam® Following Octapharma’s Implementation of Enhanced Safety Measures


Product Expected to Be Available for Distribution in a Few Weeks   HOBOKEN, N.J. (November 4, 2011) – The U.S. Food and Drug Administration (FDA) yesterday cleared the way for the U.S. market return of octagam® [Immune...

European Commission adopts European Medicines Agency's (EMA) recommendation to lift the suspension of the marketing authorization of octagam® and octagam®10%.


On 30 May 2011 The European Commission adopted the EMA's recommendation of 14 April 2011 revised on May 12, 2011 to lift the suspension of the marketing authorization of octagam® and octagam®10%, thus allowing both products back...

Octapharma Statement Regarding the April 15, 2011 FDA Warning Letter Published on May 10, 2011


On April 15, 2011, the FDA issued a Warning Letter to Octapharma AB as a result of a manufacturing site inspection that took place in January 2011 at Octapharma's Stockholm facility. This Warning Letter related to the inspection...

Octapharma Results 2010


Lachen, April 27, 2011   The year 2010 has shown the importance for a solid financial basis for the Octapharma Group, a position that the company has established over years of financially responsible management. The...